Durvalumab after Chemoradiotherapy in Stage III Non–Small-Cell Lung Cancer
Open accessThe DOI matches its Crossref record; 22 of the 22 references it cites were found in a registry or an index.
Abstract
BACKGROUND: Most patients with locally advanced, unresectable, non-small-cell lung cancer (NSCLC) have disease progression despite definitive chemoradiotherapy (chemotherapy plus concurrent radiation therapy). This phase 3 study compared the anti-programmed death ligand 1 antibody durvalumab as consolidation therapy with placebo in patients with stage III NSCLC who did not have disease progression after two or more cycles of platinum-based chemoradiotherapy. METHODS: We randomly assigned patients, in a 2:1 ratio, to receive durvalumab (at a dose of 10 mg per kilogram of body weight intravenously) or placebo every 2 weeks for up to 12 months. The study drug was administered 1 to 42 days after the patients had received chemoradiotherapy. The coprimary end points were progression-free survival (as assessed by means of blinded independent central review) and overall survival (unplanned for the interim analysis). Secondary end points included 12-month and 18-month progression-free survival rates, the objective response rate, the duration of response, the time to death or distant metastasis, and safety. RESULTS: Of 713 patients who underwent randomization, 709 received consolidation therapy (473 received durvalumab and 236 received placebo). The median progression-free survival from randomization was 16.8 months (95% confidence interval [CI], 13.0 to 18.1) with durvalumab versus 5.6 months (95% CI, 4.6 to 7.8) with placebo (stratified hazard ratio for disease progression or death, 0.52; 95% CI, 0.42 to 0.65; P<0.001); the 12-month progression-free survival rate was 55.9% versus 35.3%, and the 18-month progression-free survival rate was 44.2% versus 27.0%. The response rate was higher with durvalumab than with placebo (28.4% vs. 16.0%; P<0.001), and the median duration of response was longer (72.8% vs. 46.8% of the patients had an ongoing response at 18 months). The median time to death or distant metastasis was longer with durvalumab than with placebo (23.2 months vs. 14.6 months; P<0.001). Grade 3 or 4 adverse events occurred in 29.9% of the patients who received durvalumab and 26.1% of those who received placebo; the most common adverse event of grade 3 or 4 was pneumonia (4.4% and 3.8%, respectively). A total of 15.4% of patients in the durvalumab group and 9.8% of those in the placebo group discontinued the study drug because of adverse events. CONCLUSIONS: Progression-free survival was significantly longer with durvalumab than with placebo. The secondary end points also favored durvalumab, and safety was similar between the groups. (Funded by AstraZeneca; PACIFIC ClinicalTrials.gov number, NCT02125461 .).
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Clinical benefi t with maintenance ICT in specifi c settings was demonstrated in patients with nonsmall cell lung cancer (NSCLC; ref.50 ), extensive-stage small cell lung cancer ( 51,52 ), and bladder cancer ( 53 ), leading to FDA approvals in these tumor types.”
From The Next Decade of Immune Checkpoint Therapy (2021) · cites this paper as [50]
In the citing paper
“By contrast, ICB has shown promise in the adjuvant setting in patients with melanoma or NSCLC57–59”
From Enhancing cancer immunotherapy using antiangiogenics: opportunities and challenges (2018) · cites this paper as [58]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
The blockade of immune checkpoints in cancer immunotherapy
Pardoll, D. M. (2012) · Nature Reviews Cancer · doi:10.1038/nrc3239 · Cited by 13,838
Immune Checkpoint Blockade in Cancer Therapy
Postow, M. A., Callahan, M. K., & Wolchok, J. D. (2015) · Journal of Clinical Oncology · doi:10.1200/jco.2014.59.4358 · Cited by 2,709
Irradiation and anti–PD-L1 treatment synergistically promote antitumor immunity in mice
Deng, L., Liang, H., Burnette, B., Beckett, M., Darga, T., Weichselbaum, R. R., & Fu, Y.-X. (2014) · Journal of Clinical Investigation · doi:10.1172/jci67313 · Cited by 2,105
Bradley, J. D., Paulus, R., Komaki, R., Masters, G., Blumenschein, G., Schild, S., Bogart, J., Hu, C., Forster, K., Magliocco, A., et al. (2015) · The Lancet Oncology · doi:10.1016/s1470-2045(14)71207-0 · Cited by 2,015
Aupérin, A., Le Péchoux, C., Rolland, E., Curran, W. J., Furuse, K., Fournel, P., Belderbos, J., Clamon, G., Ulutin, H. C., Paulus, R., et al. (2010) · Journal of Clinical Oncology · doi:10.1200/jco.2009.26.2543 · Cited by 1,878
Acquired Resistance to Fractionated Radiotherapy Can Be Overcome by Concurrent PD-L1 Blockade
Dovedi, S. J., Adlard, A. L., Lipowska-Bhalla, G., McKenna, C., Jones, S., Cheadle, E. J., Stratford, I. J., Poon, E., Morrow, M., Stewart, R., et al. (2014) · Cancer Research · doi:10.1158/0008-5472.can-14-1258 · Cited by 1,313
Kelly, K., Chansky, K., Gaspar, L. E., Albain, K. S., Jett, J., Ung, Y. C., Lau, D. H. M., Crowley, J. J., & Gandara, D. R. (2008) · Journal of Clinical Oncology · doi:10.1200/jco.2007.14.4824 · Cited by 573
Butts, C., Socinski, M. A., Mitchell, P. L., Thatcher, N., Havel, L., Krzakowski, M., Nawrocki, S., Ciuleanu, T.-E., Bosquée, L., Trigo, J. M., et al. (2014) · The Lancet Oncology · doi:10.1016/s1470-2045(13)70510-2 · Cited by 538
Hanna, N., Neubauer, M., Yiannoutsos, C., McGarry, R., Arseneau, J., Ansari, R., Reynolds, C., Govindan, R., Melnyk, A., Fisher, W., et al. (2008) · Journal of Clinical Oncology · doi:10.1200/jco.2008.17.7840 · Cited by 491
Vansteenkiste, J., De Ruysscher, D., Eberhardt, W. E. E., Lim, E., Senan, S., Felip, E., & Peters, S. (2013) · Annals of Oncology · doi:10.1093/annonc/mdt241 · Cited by 490
Research works printed but not linked: 1
- Ettinger S, Wood DE, Aisner DL, et al. Non-small cell lung cancer, Version 5.2017. J Natl Compr Canc Netw 2017; 15: 504-35.
Cited by
Items 501–600 of 1,008
Zhao, W., Jiang, W., Wang, H., He, J., Su, C., & Yu, Q. (2021) · Frontiers in Oncology · doi:10.3389/fonc.2021.703143 · Cited by 81
Jin, N., Keam, B., Cho, J., Lee, M. J., Kim, H. R., Torosyan, H., Jura, N., Ng, P. K. S., Mills, G. B., Li, H., et al. (2021) · Journal of Clinical Investigation · doi:10.1172/jci150335 · Cited by 72
Gubens, M. A., & Davies, M. J. (2019) · PubMed · doi:10.6004/jnccn.2019.5005 · Cited by 78
Assessing Therapeutic Efficacy of MEK Inhibition in a KRASG12C-Driven Mouse Model of Lung Cancer
Li, S., Liu, S., Deng, J., Akbay, E. A., Hai, J., Ambrogio, C., Zhang, L., Zhou, F., Jenkins, R. W., Adeegbe, D. O., et al. (2018) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-17-3438 · Cited by 67
Quantifying PD-L1 Expression to Monitor Immune Checkpoint Therapy: Opportunities and Challenges
Nimmagadda, S. (2020) · Cancers · doi:10.3390/cancers12113173 · Cited by 69
Chyuan, I., Chu, C., & Hsu, P. (2021) · Cancers · doi:10.3390/cancers13061188 · Cited by 71
Amodio, V., Mauri, G., Reilly, N. M., Bianchi, A. S., Siena, S., Bardelli, A., & Germano, G. (2021) · Cancers · doi:10.3390/cancers13112638 · Cited by 74
PARP mediated DNA damage response, genomic stability and immune responses
Zong, C., Zhu, T., He, J., Huang, R., Jia, R., & Shen, J. (2022) · International Journal of Cancer · doi:10.1002/ijc.33918 · Cited by 74
Cheng, J., Pan, Y., Huang, W., Huang, K., Cui, Y., Hong, W., Wang, L., Ni, D., & Tan, P. (2022) · Medical Physics · doi:10.1002/mp.15451 · Cited by 70
Zhang, L., Zhou, C., Zhang, S., Chen, X., Liu, J., Xu, F., & Liang, W. (2022) · Frontiers in Oncology · doi:10.3389/fonc.2022.939249 · Cited by 83
Remón, J., Mezquita, L., Corral, J., Vilariño, N., & Reguart, N. (2018) · Journal of Thoracic Disease · doi:10.21037/jtd.2017.12.52 · Cited by 74
From immune checkpoints to vaccines: The past, present and future of cancer immunotherapy
Osipov, A., Murphy, A. G., & Zheng, L. (2019) · Advances in cancer research · doi:10.1016/bs.acr.2019.03.002 · Cited by 77
Kleinberg, L. R., Sloan, L., Grossman, S. A., & Lim, M. K. (2019) · Neurosurgery · doi:10.1093/neuros/nyz198 · Cited by 74
When is crossover desirable in cancer drug trials and when is it problematic?
Haslam, A., & Prasad, V. K. (2018) · Annals of Oncology · doi:10.1093/annonc/mdy116 · Cited by 72
Multhoff, G., Seier, S., Stangl, S., Sievert, W., Shevtsov, M. A., Werner, C., Pockley, A. G., Blankenstein, C., Hildebrandt, M., Offner, R., et al. (2020) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-20-1141 · Cited by 66
Selection of threose nucleic acid aptamers to block PD-1/PD-L1 interaction for cancer immunotherapy
Li, X., Li, Z., & Yu, H. (2020) · Chemical Communications · doi:10.1039/d0cc06032a · Cited by 69
Doki, Y., Ueno, M., Hsu, C., Oh, D., Park, K., Yamamoto, N., Ioka, T., Hara, H., Hayama, M., Nii, M., et al. (2022) · Cancer Medicine · doi:10.1002/cam4.4593 · Cited by 73
Management of Lung Cancer in the Patient with Interstitial Lung Disease
Frank, A. J., Dagogo‐Jack, I., Dobre, I. A., Tait, S. D., Schumacher, L., Fintelmann, F. J., Fingerman, L. M., Keane, F. K., & Montesi, S. B. (2022) · The Oncologist · doi:10.1093/oncolo/oyac226 · Cited by 72
Olivares-Hernández, A., Portillo, E. G.-D., Tamayo-Velasco, Á., Figuero-Pérez, L., Zhilina-Zhilina, S., Fonseca‐Sánchez, E., & Miramontes‐González, J. P. (2023) · Annals of Translational Medicine · doi:10.21037/atm-22-4218 · Cited by 81
Cancer Biomarkers and Precision Oncology: A Review of Recent Trends and Innovations
AlDoughaim, M., Alsuhebany, N., Alzahrani, M., Alqahtani, T., Alghamdi, S. S., Badreldin, H. A., & Alshaykh, H. A. (2024) · Clinical Medicine Insights Oncology · doi:10.1177/11795549241298541 · Cited by 87
Verma, V., Haque, W. M., Cushman, T. R., Lin, C. H., Simone, C. B., Chang, J. Y., McClelland, S., & Welsh, J. W. (2019) · Journal of Immunotherapy · doi:10.1097/cji.0000000000000253 · Cited by 67
Martinez-Morilla, S., McGuire, J., Gaule, P., Moore, L., Acs, B., Cougot, D., Gown, A. M., Yaziji, H., Wang, W.-L., Cartun, R. W., et al. (2020) · Laboratory Investigation · doi:10.1038/s41374-019-0295-9 · Cited by 66
Kato, S., Okamura, R., Kumaki, Y., Ikeda, S., Nikanjam, M., Eskander, R. N., Goodman, A. M., Lee, S., Glenn, S. T., Dressman, D. C., et al. (2020) · OncoImmunology · doi:10.1080/2162402x.2019.1708065 · Cited by 70
Naidoo, J., Nishino, M., Patel, S. P., Shankar, B., Rekhtman, N., Illei, P. B., & Camus, P. (2020) · Clinical Lung Cancer · doi:10.1016/j.cllc.2020.02.025 · Cited by 74
Radiation therapy-induced metastasis: radiobiology and clinical implications
Blyth, B. J., Cole, A., MacManus, M. P., & Martin, O. A. (2017) · Clinical & Experimental Metastasis · doi:10.1007/s10585-017-9867-5 · Cited by 65
Nichetti, F., Ligorio, F., Zattarin, E., Signorelli, D., Prelaj, A., Proto, C., Galli, G., Marra, A., Apollonio, G., Porcu, L., et al. (2019) · Cancers · doi:10.3390/cancers12010067 · Cited by 66
Immunotherapy in non-small cell lung cancer: update and new insights
Mielgo-Rubio, X., Uribelarrea, E. A., Cortés, L. Q., & Moyano, M. S. (2021) · Journal of Clinical and Translational Research · doi:10.18053/jctres.07.202101.001 · Cited by 78
Khaddour, K., Jonna, S., Deneka, A. Y., Patel, J. D., Abazeed, M. E., Golemis, E. A., Borghaei, H., & Boumber, Y. (2021) · Cancers · doi:10.3390/cancers13133164 · Cited by 71
Zhao, B., Wu, B. C., Feng, N., Zhang, X., Zhang, X., Wei, Y., & Zhang, W. (2023) · Journal of Hematology & Oncology · doi:10.1186/s13045-023-01426-4 · Cited by 81
Challenges Coexist with Opportunities: Spatial Heterogeneity Expression of PD‐L1 in Cancer Therapy
Wang, Y., Zhou, Y., Yang, L., Lei, L., He, B., Cao, J., & Gao, H. (2023) · Advanced Science · doi:10.1002/advs.202303175 · Cited by 86
Filippi, A. R., Bar, J., CHOUAID, C., Christoph, D. C., Field, J. K., Fietkau, R., Garassino, M. C., Garrido, P., Haakensen, V. D., Kao, S. C.-H., et al. (2024) · ESMO Open · doi:10.1016/j.esmoop.2024.103464 · Cited by 76
Wang, Y., Safi, M., Hirsch, F. R., Lu, S., Peters, S., Govindan, R., Rosell, R., Park, K., & Zhang, J. J. (2025) · Nature Reviews Clinical Oncology · doi:10.1038/s41571-024-00979-8 · Cited by 84
Mandal, K., Barik, G. K., & Santra, M. K. (2025) · Molecular Cancer · doi:10.1186/s12943-025-02400-z · Cited by 78
The evolving toxicity profile of SBRT for lung cancer
Thompson, M., & Rosenzweig, K. E. (2018) · Translational Lung Cancer Research · doi:10.21037/tlcr.2018.10.06 · Cited by 73
TIM-3 expression in breast cancer
Burugu, S., Gao, D., Leung, S. C. Y., Chia, S., & Nielsen, T. O. (2018) · OncoImmunology · doi:10.1080/2162402x.2018.1502128 · Cited by 72
Achievements and futures of immune checkpoint inhibitors in non-small cell lung cancer
Qiu, Z., Chen, Z., Zhang, C., & Zhong, W. (2019) · Experimental Hematology and Oncology · doi:10.1186/s40164-019-0143-z · Cited by 65
Lü, S., Casarini, I., Kato, T., Cobo, M., Özgüroğlu, M., Hodge, R. A., van der Gronde, T., Saggese, M., & Ramalingam, S. S. (2021) · Clinical Lung Cancer · doi:10.1016/j.cllc.2020.11.004 · Cited by 70
Self-citationClinical characterization of colitis arising from anti-PD-1 based therapy
Wang, D. Y., Mooradian, M. J., Kim, D. W., Shah, N. J., Fenton, S. E., Conry, R. M., Mehta, R. J., Silk, A. W., Zhou, A. Y., Compton, M., et al. (2018) · OncoImmunology · doi:10.1080/2162402x.2018.1524695 · Cited by 69
A radiomic approach for adaptive radiotherapy in non-small cell lung cancer patients
Ramella, S., Fiore, M., Greco, C., Cordelli, E., Sicilia, R., Merone, M., Molfese, E., Miele, M., Cornacchione, P., Ippolito, E., et al. (2018) · PLoS ONE · doi:10.1371/journal.pone.0207455 · Cited by 69
Criss, S. D., Mooradian, M. J., Sheehan, D. F., Zubiri, L., Lumish, M. A., Gainor, J. F., Reynolds, K. L., & Kong, C. Y. (2018) · JAMA Oncology · doi:10.1001/jamaoncol.2018.5449 · Cited by 65
Lee, N. C. J., Kelly, J. R., Park, H. S.-M., An, Y., Judson, B. L., Burtness, B. A., & Husain, Z. A. (2018) · Oral Oncology · doi:10.1016/j.oraloncology.2018.08.001 · Cited by 63
mRNA-Based Therapeutics in Cancer Treatment
Sun, H., Zhang, Y., Wang, G., Yang, W., & Xu, Y. (2023) · Pharmaceutics · doi:10.3390/pharmaceutics15020622 · Cited by 68
The evolving landscape of immunotherapy in small-cell lung cancer: A focus on predictive biomarkers
Gelsomino, F., Lamberti, G., Parisi, C., Casolari, L., Melotti, B., Sperandi, F., & Ardizzoni, A. (2019) · Cancer Treatment Reviews · doi:10.1016/j.ctrv.2019.08.003 · Cited by 67
Radiation as an In Situ Auto-Vaccination: Current Perspectives and Challenges
Goto, T. (2019) · Vaccines · doi:10.3390/vaccines7030100 · Cited by 66
Stage III Non-small Cell Lung Cancer Management in England
Adizie, J. B., Khakwani, A., Beckett, P., Navani, N., West, D., Woolhouse, I., & Harden, S. (2019) · Clinical Oncology · doi:10.1016/j.clon.2019.07.020 · Cited by 65
Zamarin, D., Hamid, O., Nayak-Kapoor, A., Sahebjam, S., Sznol, M., Collaku, A., Fox, F. E., Marshall, M. A., & Hong, D. S. (2020) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-20-0328 · Cited by 68
Adverse Effects of Anti-PD-1/PD-L1 Therapy in Non-small Cell Lung Cancer
Su, C., Wang, H., Liu, Y., Guo, Q., Zhang, L., Li, J., Zhou, W., Yan, Y., Zhou, X., & Zhang, J. (2020) · Frontiers in Oncology · doi:10.3389/fonc.2020.554313 · Cited by 72
Joseph, N., McWilliam, A., Kennedy, J., Haslett, K., Mahil, J., Gavarraju, A., Mistry, H. B., van Herk, M., Finn, C. F., & Choudhury, A. (2019) · Radiotherapy and Oncology · doi:10.1016/j.radonc.2019.03.008 · Cited by 65
Review of checkpoint immunotherapy for the management of non-small cell lung cancer
Raju, S., Joseph, R., & Sehgal, S. (2018) · ImmunoTargets and Therapy · doi:10.2147/itt.s125070 · Cited by 69
Nanomaterials for Combinational Radio–Immuno Oncotherapy
Wang, J., Li, Z., Wang, Z., Yu, Y., Li, D., Li, B., & Ding, J. (2020) · Advanced Functional Materials · doi:10.1002/adfm.201910676 · Cited by 63
Kim, J., Hong, J., Lee, J., Lahiji, S. F., & Kim, Y. (2021) · Journal of Controlled Release · doi:10.1016/j.jconrel.2021.02.002 · Cited by 65
Self-citationOza, B., Frangou, E., Smith, B., Bryant, H., Kaplan, R. S., Choodari‐Oskooei, B., Powles, T., Stewart, G. D., Albiges, L. K., Bex, A., et al. (2021) · Contemporary Clinical Trials · doi:10.1016/j.cct.2021.106482 · Cited by 71
Lung Cancer: Targeted Therapy in 2025
Bouchard, N., & Daaboul, N. (2025) · Current Oncology · doi:10.3390/curroncol32030146 · Cited by 80
Almawash, S. (2025) · Cancers · doi:10.3390/cancers17050880 · Cited by 78
Emerging biomarkers for the combination of radiotherapy and immune checkpoint blockers
Lhuillier, C., Vanpouille-Box, C., Galluzzi, L., Formenti, S. C., & Demaria, S. (2018) · Seminars in Cancer Biology · doi:10.1016/j.semcancer.2017.12.007 · Cited by 62
Recent success and limitations of immune checkpoint inhibitors for cancer: A lesson from melanoma
Ottaviano, M., De Placido, S., & Ascierto, P. A. (2019) · Virchows Archiv · doi:10.1007/s00428-019-02538-4 · Cited by 57
Cancer immunotherapy: the art of targeting the tumor immune microenvironment
da Silva, J. L., dos Santos, A. L. S., Nunes, N. C. C., da Silva, F. D. M. L., Ferreira, C. G., & de Melo, A. C. (2019) · Cancer Chemotherapy and Pharmacology · doi:10.1007/s00280-019-03894-3 · Cited by 67
A framework for modeling radiation induced lymphopenia in radiotherapy
Jin, J., Mereniuk, T. R., Yalamanchali, A., Wang, W., Machtay, M. X., Kong, F., & Ellsworth, S. G. (2019) · Radiotherapy and Oncology · doi:10.1016/j.radonc.2019.11.014 · Cited by 67
Our current understanding of checkpoint inhibitor therapy in cancer immunotherapy
Goleva, E., Lyubchenko, T. A., Kraehenbuehl, L., Lacouture, M. E., Leung, D. Y. M., & Kern, J. A. (2021) · Annals of Allergy Asthma & Immunology · doi:10.1016/j.anai.2021.03.003 · Cited by 64
Sun, W., Zhang, Q., Wang, R., Yang, L., Sun, Y., & Yang, L. (2021) · Frontiers in Oncology · doi:10.3389/fonc.2021.648687 · Cited by 71
Appleton, E. S., Hassan, J., Hak, C. C. W., Sivamanoharan, N., Wilkins, A. C., Samson, A., Lab), M. O. (., Harrington, K. J., Melcher, A. A., & Wennerberg, E. (2021) · Frontiers in Immunology · doi:10.3389/fimmu.2021.754436 · Cited by 68
Qiu, Q., Xing, L., Wang, Y., Feng, A., & Wen, Q. (2022) · Frontiers in Immunology · doi:10.3389/fimmu.2022.870842 · Cited by 68
Wang, Y., Zhang, T., Wang, J., Zhou, Z., Liu, W., Xiao, Z., Deng, L., Feng, Q., Wang, X., Lv, J., et al. (2023) · International Journal of Radiation Oncology*Biology*Physics · doi:10.1016/j.ijrobp.2022.12.042 · Cited by 69
Combining radiation plus immunotherapy to improve systemic immune response
Cushman, T. R., Gomez, D. R., Kumar, R., Likacheva, A., Chang, J. Y., Cadena, A. P., Paris, S., & Welsh, J. W. (2018) · Journal of Thoracic Disease · doi:10.21037/jtd.2018.01.130 · Cited by 64
Petty, W. J., Urbanic, J. J., Ahmed, T., Hughes, R. T., Levine, B. J., Rusthoven, K. E., Papagikos, M. A., Ruiz, J., Lally, B. E., Chan, M. D., et al. (2018) · International Journal of Radiation Oncology*Biology*Physics · doi:10.1016/j.ijrobp.2018.06.400 · Cited by 66
Durvalumab in cancer medicine: a comprehensive review
Argote, J. A., & Dasanu, C. A. (2019) · Expert Opinion on Biological Therapy · doi:10.1080/14712598.2019.1635115 · Cited by 64
Eckert, F., Zwirner, K., Boeke, S., Thorwarth, D., Zips, D., & Huber, S. M. (2019) · Frontiers in Immunology · doi:10.3389/fimmu.2019.00407 · Cited by 62
Cushman, T. R., Jones, B. L., Akhavan, D., Rusthoven, C. G., Verma, V., Salgia, R., Sedrak, M. S., Massarelli, E., Welsh, J. W., & Amini, A. (2020) · Clinical Lung Cancer · doi:10.1016/j.cllc.2020.09.004 · Cited by 68
Impact of PET/CT for Assessing Response to Immunotherapy—A Clinical Perspective
Lang, D., Wahl, G., Poier-Fabian, N., Graf, S., Kiesl, D., Lamprecht, B., & Gabriel, M. (2020) · Journal of Clinical Medicine · doi:10.3390/jcm9113483 · Cited by 62
A Gene Mutation Signature Predicting Immunotherapy Benefits in Patients With NSCLC
Pan, D., Hu, A. Y., Antonia, S. J., & Li, C. (2020) · Journal of Thoracic Oncology · doi:10.1016/j.jtho.2020.11.021 · Cited by 68
Self-citationSocinski, M. A., Özgüroğlu, M., Villegas, A. E., Daniel, D. B., Vicente, D., Murakami, S., Hui, R., Gray, J. E., Park, K., Vincent, M. D., et al. (2021) · Clinical Lung Cancer · doi:10.1016/j.cllc.2021.05.009 · Cited by 64
Self-citationSystemic and Radiation Therapy Approaches for Locally Advanced Non–Small-Cell Lung Cancer
Higgins, K. A., Puri, S., & Gray, J. E. (2022) · Journal of Clinical Oncology · doi:10.1200/jco.21.01707 · Cited by 68
Self-citationLi, M. S. C., Mok, K. K. S., & Mok, T. S. K. (2023) · Annals of Translational Medicine · doi:10.21037/atm-22-4444 · Cited by 76
The immunological consequences of radiation‐induced DNA damage
Wilkins, A. C., Patin, E. C., Harrington, K. J., & Melcher, A. A. (2019) · The Journal of Pathology · doi:10.1002/path.5232 · Cited by 59
Heeren, A. M., Rotman, J., Stam, A. G. M., Pocorni, N., Gassama, A. A., Samuels, S., Bleeker, M. C. G., Mom, C. H., Zijlmans, H. J. M. A. A., Kenter, G. G., et al. (2019) · Journal for ImmunoTherapy of Cancer · doi:10.1186/s40425-019-0526-z · Cited by 68
Longo, V., Brunetti, O., Azzariti, A., Galetta, D., Nardulli, P., Leonetti, F., & Silvestris, N. (2019) · Cancers · doi:10.3390/cancers11040539 · Cited by 66
Zhan, J., Wang, P., Li, S., Song, J., He, H., Wang, Y., Liu, Z., Wang, F., Bai, H., Fang, W., et al. (2019) · Theranostics · doi:10.7150/thno.29463 · Cited by 63
Neoplasia and intraocular inflammation: From masquerade syndromes to immunotherapy-induced uveitis
Touhami, S., Audo, I. S., Terrada, C., Gaudric, A., LeHoang, P., Touitou, V., & Bodaghi, B. (2019) · Progress in Retinal and Eye Research · doi:10.1016/j.preteyeres.2019.05.002 · Cited by 63
A Computational Model of Neoadjuvant PD-1 Inhibition in Non-Small Cell Lung Cancer
Jafarnejad, M., Gong, C., Gabrielson, E., Bartelink, I. H., Vicini, P., Wang, B., Narwal, R., Roskos, L., & Popel, A. S. (2019) · The AAPS Journal · doi:10.1208/s12248-019-0350-x · Cited by 62
Imaging of Precision Therapy for Lung Cancer: Current State of the Art
Park, H., Sholl, L. M., Hatabu, H., Awad, M. M., & Nishino, M. (2019) · Radiology · doi:10.1148/radiol.2019190173 · Cited by 64
Tumour Microenvironment and Immune Evasion in EGFR Addicted NSCLC: Hurdles and Possibilities
Santaniello, A., Napolitano, F., Servetto, A., Placido, P. D., Silvestris, N., Bianco, C., Formisano, L., & Bianco, R. (2019) · Cancers · doi:10.3390/cancers11101419 · Cited by 61
She, L., Hu, H., Liao, M., Xia, X., Shi, Y., Yao, L., Ding, D., Zhu, Y., Zeng, S., Shen, L., et al. (2019) · Lung Cancer · doi:10.1016/j.lungcan.2019.10.017 · Cited by 65
Radiation pneumonitis in lung cancer patients treated with chemoradiation plus durvalumab
Shaverdian, N., Thor, M., Shepherd, A. F., Offin, M. D., Jackson, A., Wu, A. J.-C., Gelblum, D. Y., Yorke, E. D., Simone, C. B., Chaft, J. E., et al. (2020) · Cancer Medicine · doi:10.1002/cam4.3113 · Cited by 66
Current Surgical Indications for Non-Small-Cell Lung Cancer
Deboever, N., Mitchell, K. G., Feldman, H. A., Cascone, T., & Sepesi, B. (2022) · Cancers · doi:10.3390/cancers14051263 · Cited by 74
Role of Consolidation Durvalumab in Patients With EGFR- and HER2-Mutant Unresectable Stage III NSCLC
Hellyer, J. A., Aredo, J. V., Das, M. S., Ramchandran, K. J., Padda, S. K., Neal, J. W., & Wakelee, H. A. (2021) · Journal of Thoracic Oncology · doi:10.1016/j.jtho.2020.12.020 · Cited by 60
Ruysscher, D. D., Wauters, E., Jendrossek, V., Filippi, A. R., Revel, M., Finn, C. F., Naidoo, J., Ramella, S., Gückenberger, M., Ricardi, U., et al. (2025) · Radiotherapy and Oncology · doi:10.1016/j.radonc.2025.110837 · Cited by 72
Lin, A. J., Gang, M., Rao, Y. J., Campian, J. L., Daly, M. D., Gay, H. A., Oppelt, P., Jackson, R. S., Rich, J. T., Paniello, R. C., et al. (2019) · JAMA Otolaryngology–Head & Neck Surgery · doi:10.1001/jamaoto.2019.0034 · Cited by 62
Teramoto, K., Igarashi, T., Kataoka, Y., Ishida, M., Hanaoka, J., Sumimoto, H., & Daigo, Y. (2019) · Lung Cancer · doi:10.1016/j.lungcan.2019.09.013 · Cited by 59
Wagner, G., Stollenwerk, H. K., Klerings, I., Pecherstorfer, M., Gartlehner, G., & Singer, J. (2020) · OncoImmunology · doi:10.1080/2162402x.2020.1774314 · Cited by 63
Pilones, K. A., Hensler, M., Daviaud, C., Kraynak, J., Fucikova, J. P., Galluzzi, L., Demaria, S., & Formenti, S. C. (2020) · OncoImmunology · doi:10.1080/2162402x.2020.1830524 · Cited by 67
Affolter, T., Llewellyn, H. P., Bartlett, D. W., Zong, Q., Xia, S., Torti, V., & Ji, C. (2019) · PLOS ONE · doi:10.1371/journal.pone.0217276 · Cited by 56
Offin, M. D., Shaverdian, N., Rimner, A., Lobaugh, S. M., Shepherd, A. F., Simone, C. B., Gelblum, D. Y., Wu, A. J.-C., Lee, N. Y., Kris, M. G., et al. (2020) · Radiotherapy and Oncology · doi:10.1016/j.radonc.2020.04.047 · Cited by 63
Cancer neoantigens as potential targets for immunotherapy
Ma, W., Pham, B., & Li, T. (2021) · Clinical & Experimental Metastasis · doi:10.1007/s10585-021-10091-1 · Cited by 68
Saito, G., Oya, Y., Taniguchi, Y., Kawachi, H., Fujimoto, D., Matsumoto, H., Iwasawa, S., Suzuki, H., Niitsu, T., Miyauchi, E., et al. (2021) · Lung Cancer · doi:10.1016/j.lungcan.2021.08.019 · Cited by 63
Self-citationVaz, S. C., Adam, J. A., Bolton, R. C. D., Véra, P., van Elmpt, W., Herrmann, K., Hicks, R. J., Lievens, Y. N., Santos, A., Schöder, H. M., et al. (2022) · European Journal of Nuclear Medicine and Molecular Imaging · doi:10.1007/s00259-021-05624-5 · Cited by 64
18F FDG PET/CT and Novel Molecular Imaging for Directing Immunotherapy in Cancer
Hughes, D. J., Subesinghe, M., Taylor, B. P., Billè, A., Spicer, J. F., Papa, S., Goh, V., & Cook, G. (2022) · Radiology · doi:10.1148/radiol.212481 · Cited by 62
Ross, H. J., Kozono, D., Wang, X. F., Urbanic, J. J., Williams, T. M., Nelson, G. D., Carbone, D. P., Chung, D., Robb, R. N., Byun, W. Y., et al. (2024) · JAMA Oncology · doi:10.1001/jamaoncol.2024.1897 · Cited by 67
Studying protein–protein interactions: Latest and most popular approaches
Akbarzadeh, S., Coşkun, Ö., & Günçer, B. (2024) · Journal of Structural Biology · doi:10.1016/j.jsb.2024.108118 · Cited by 66
2017–2018 Scientific Advances in Thoracic Oncology: Small Cell Lung Cancer
Zimmerman, S., Das, A., Wang, S., Julian, R. A., Gandhi, L., & Wolf, J. (2019) · Journal of Thoracic Oncology · doi:10.1016/j.jtho.2019.01.022 · Cited by 62
Zhao, Q., Chen, G., Ye, L., Shi, S., Du, S., Zeng, Z., & He, J. (2019) · Radiation Oncology · doi:10.1186/s13014-019-1287-z · Cited by 68
Metadata
- Authors
- Antonia, S. J., Villegas, A., Daniel, D., Vicente, D., Murakami, S., Hui, R., Yokoi, T., Chiappori, A., Lee, K. H., de Wit, M., Cho, B. C., Bourhaba, M., Quantin, X., Tokito, T., Mekhail, T., Planchard, D., Kim, Y.-C., Karapetis, C. S., Hiret, S., Ostoros, G., Kubota, K., Gray, J. E., Paz-Ares, L., de Castro Carpeño, J., Wadsworth, C., Melillo, G., Jiang, H., Huang, Y., Dennis, P. A., & Özgüroğlu, M.
- Affiliations
- Institut Gustave Roussy (FR)
- From the H. Lee Moffitt Cancer Center and Research Institute, Tampa (S.J.A., A.C., J.E.G.), Cancer Specialists of North Florida, Jacksonville (A.V.), and Florida Hospital Cancer Institute, Orlando (T.M.) — all in Florida; Tennessee Oncology, Chattanooga, and Sarah Cannon Research Institute, Nashville — both in Tennessee (D.D.); Hospital Universitario Virgen Macarena, Seville (D.V.), and Hospital Universitario 12 de Octubre, Centro de Investigación Biomédica en Red de Cáncer, Universidad Complutense and...
- ORCID
- Antonia, Scott J.
- Villegas, Augusto
- Daniel, Davey
- Vicente, David
- Murakami, Shuji
- Hui, Rina
- Yokoi, Takashi
- Chiappori, Alberto
- Lee, Ki H.
- Cho, Byoung C.
- Quantin, Xavier
- Tokito, Takaaki
- Planchard, David
- Kim, Young-Chul
- Karapetis, Christos S.
- Hiret, Sandrine
- Ostoros, Gyula
- Kubota, Kaoru
- Gray, Jhanelle E.
- Paz-Ares, Luis
- Jiang, Haiyi
- Huang, Yifan
- Özgüroğlu, Mustafa
- Venue
- New England Journal of Medicine
- Publisher
- Massachusetts Medical Society
- Published
- 2017-11-16
- Volume
- 377
- Issue
- 20
- Pages
- 1919-1929
- ISSN
- 0028-4793 (ISSN-L)
- 1533-4406
- OpenAlex
- W2753065806
- Cited by
- 4,593
- References
- 22
- Citations by year
- 2026: 380 · 2025: 463 · 2024: 496 · 2023: 548 · 2022: 555 · 2021: 625 · 2020: 563 · 2019: 463 · 2018: 451 · 2017: 46
- FWCI
- 183.64
- Type
- journal article
- Language
- en
- Open access
- bronze
- doi.org
- Locations
- New England Journal of Medicine (publishedVersion)
- PubMed (publishedVersion)
- QUT ePrints (Queensland University of Technology) (submittedVersion)
- HAL (submittedVersion)
- YUHSpace (Yonsei University Medical Library) (submittedVersion, cc-by-nc-nd)
- Lirias (submittedVersion)
- ORBi (University of Liège) (submittedVersion, other-oa)
- Radboud Repository (Radboud University) (submittedVersion)
- RISalud Institutional Health Repository of Andalucía (submittedVersion, other-oa)
- Funders
- AstraZeneca
- Cancer Research UK (20465)
- Topics
- Health Sciences › Medicine › Oncology › Cancer Immunotherapy and Biomarkers
- Health Sciences › Medicine › Pulmonary and Respiratory Medicine › Lung Cancer Diagnosis and Treatment
- Health Sciences › Medicine › Pulmonary and Respiratory Medicine › Lung Cancer Treatments and Mutations
- Keywords
- durvalumab, non-small cell lung cancer, stage III NSCLC, consolidation therapy, chemoradiotherapy, PD-L1 inhibitors, progression-free survival, overall survival, objective response rate, locally advanced unresectable lung cancer, immune checkpoint inhibitors, platinum-based chemotherapy, radiotherapy, distant metastasis, treatment safety, adverse events
- MeSH terms
- Adult, Aged, Aged, 80 and over, Antibodies, Monoclonal, Antineoplastic Agents, Carcinoma, Non-Small-Cell Lung, Female, Humans, Lung Neoplasms, Male, Middle Aged, Neoplasm Staging, Disease-Free Survival, Kaplan-Meier Estimate, Intention to Treat Analysis, Chemoradiotherapy, B7-H1 Antigen
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.